Adnan N Kiani1, Wendy S Post, Laurence S Magder, Michelle Petri. 1. Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine Baltimore, 1830 East Monument Street Suite 7500, Baltimore, MD 21205, USA.
Abstract
OBJECTIVES: Cardiovascular disease remains the major cause of death in SLE. We assessed the degree to which cardiovascular risk factors (CVRFs) and disease activity were associated with 2-year changes in measures of subclinical atherosclerosis. METHODS:One hundred and eighty-seven SLE patients participating in aplacebo-controlled trial of atorvastatin underwent multi-detector CT [for coronary artery calcium (CAC)] and carotid duplex [for carotid intima-media thickness (IMT) and carotid plaque] twice, 2 years apart. During the 2 years, patients were assessed every 3 months for CVRF. Both groups were combined for analysis, as atorvastatin did not differ from placebo in preventing progression of coronary calcium. We examined the correlation between these clinical measures and progression of CAC, IMT and plaque during the follow-up period. RESULTS: In an analysis adjusting for age, gender and ethnicity, CAC progression was positively associated with total serum cholesterol measured over the 2-year period (P = 0.04) and smoking (P = 0.003). Carotid IMT progression was associated with systolic BP (P = 0.003), high-sensitivity CRP (hsCRP) (P = 0.013) and white blood cell (WBC) count (P = 0.029). Carotid plaque progression, defined as patients without carotid plaque at baseline with subsequent development of plaque at follow-up, was associated with systolic BP (P = 0.003), WBC count (P = 0.02), physician's global assessment (P = 0.05), blood lymphocyte count (P = 0.048), urine protein (P = 0.017) and duration of SLE (P = 0.019). CONCLUSION: Our data did not provide evidence of an association between measures of SLE disease activity (SLEDAI, anti-dsDNA, anti-phospholipid and treatment) and progression of subclinical atherosclerosis. Age and hypertension were associated with the progression of carotid IMT and plaque. Age, smoking and cholesterol were associated with progression of CAC.
RCT Entities:
OBJECTIVES:Cardiovascular disease remains the major cause of death in SLE. We assessed the degree to which cardiovascular risk factors (CVRFs) and disease activity were associated with 2-year changes in measures of subclinical atherosclerosis. METHODS: One hundred and eighty-seven SLEpatients participating in a placebo-controlled trial of atorvastatin underwent multi-detector CT [for coronary artery calcium (CAC)] and carotid duplex [for carotid intima-media thickness (IMT) and carotid plaque] twice, 2 years apart. During the 2 years, patients were assessed every 3 months for CVRF. Both groups were combined for analysis, as atorvastatin did not differ from placebo in preventing progression of coronary calcium. We examined the correlation between these clinical measures and progression of CAC, IMT and plaque during the follow-up period. RESULTS: In an analysis adjusting for age, gender and ethnicity, CAC progression was positively associated with total serum cholesterol measured over the 2-year period (P = 0.04) and smoking (P = 0.003). Carotid IMT progression was associated with systolic BP (P = 0.003), high-sensitivity CRP (hsCRP) (P = 0.013) and white blood cell (WBC) count (P = 0.029). Carotid plaque progression, defined as patients without carotid plaque at baseline with subsequent development of plaque at follow-up, was associated with systolic BP (P = 0.003), WBC count (P = 0.02), physician's global assessment (P = 0.05), blood lymphocyte count (P = 0.048), urine protein (P = 0.017) and duration of SLE (P = 0.019). CONCLUSION: Our data did not provide evidence of an association between measures of SLE disease activity (SLEDAI, anti-dsDNA, anti-phospholipid and treatment) and progression of subclinical atherosclerosis. Age and hypertension were associated with the progression of carotid IMT and plaque. Age, smoking and cholesterol were associated with progression of CAC.
Authors: C J Halkes; H van Dijk; P P de Jaegere; H W Plokker; Y van Der Helm; D W Erkelens; M Castro Cabezas Journal: Arterioscler Thromb Vasc Biol Date: 2001-09 Impact factor: 8.311
Authors: Andrew D Mackinnon; Paula Jerrard-Dunne; Matthias Sitzer; Alexandra Buehler; Stefan von Kegler; Hugh S Markus Journal: Stroke Date: 2004-07-08 Impact factor: 7.914
Authors: J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal Journal: Arthritis Rheum Date: 2001-10
Authors: Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon Journal: N Engl J Med Date: 2003-12-18 Impact factor: 91.245
Authors: Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein Journal: N Engl J Med Date: 2003-12-18 Impact factor: 91.245
Authors: George T Kondos; Julie Anne Hoff; Alexander Sevrukov; Martha L Daviglus; Daniel B Garside; Stephen S Devries; Eva V Chomka; Kiang Liu Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: K Manger; M Kusus; C Forster; D Ropers; W G Daniel; J R Kalden; S Achenbach; B Manger Journal: Ann Rheum Dis Date: 2003-09 Impact factor: 19.103
Authors: Adnan N Kiani; Hong Fang; Ehtisham Akhter; Carmen Quiroga; Nancy Simpson; Petar Alaupovic; Laurence S Magder; Michelle Petri Journal: Arthritis Care Res (Hoboken) Date: 2015-03 Impact factor: 4.794
Authors: Kayode J Bello; Hong Fang; Parastoo Fazeli; Waleed Bolad; Mary Corretti; Laurence S Magder; Michelle Petri Journal: Rheumatol Int Date: 2013-07-02 Impact factor: 2.631